{"id":"monoclonal-antibodies-gd2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GD2 is a glycolipid that is overexpressed on the surface of neuroblastoma cells. By targeting GD2, GD2-targeting monoclonal antibodies can selectively kill cancer cells while sparing normal cells. This mechanism of action is thought to be responsible for the therapeutic effects of these antibodies.","oneSentence":"GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:03.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroblastoma"}]},"trialDetails":[{"nctId":"NCT01711554","phase":"PHASE1","title":"Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-04","conditions":"Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":27},{"nctId":"NCT03363373","phase":"PHASE2","title":"Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow","status":"RECRUITING","sponsor":"Y-mAbs Therapeutics","startDate":"2018-04-03","conditions":"Neuroblastoma","enrollment":122},{"nctId":"NCT05489887","phase":"PHASE2","title":"Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2022-09-14","conditions":"Neuroblastoma","enrollment":93},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT07261241","phase":"PHASE2","title":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","status":"NOT_YET_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2026-07-31","conditions":"Neuroblastoma","enrollment":118},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT02914405","phase":"PHASE1","title":"Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2018-05-24","conditions":"Neuroblastoma","enrollment":44},{"nctId":"NCT02502786","phase":"PHASE2","title":"Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-07","conditions":"Recurrent Osteosarcoma","enrollment":46},{"nctId":"NCT07027748","phase":"PHASE1","title":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Steven DuBois, MD","startDate":"2025-06-27","conditions":"Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma","enrollment":18},{"nctId":"NCT06026657","phase":"PHASE1, PHASE2","title":"Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Margaret Gatti-Mays","startDate":"2024-04-02","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":42},{"nctId":"NCT06948994","phase":"PHASE1, PHASE2","title":"A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Women and Children's Medical Center","startDate":"2025-05-01","conditions":"Neuroblastoma, GD2 Antibody, Autologous NK Cell","enrollment":15},{"nctId":"NCT00445965","phase":"PHASE2","title":"Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-01","conditions":"Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer","enrollment":78},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT02258815","phase":"PHASE2","title":"CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","startDate":"2010-08","conditions":"Neuroblastoma Recurrent","enrollment":35},{"nctId":"NCT06071897","phase":"PHASE3","title":"Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-09-01","conditions":"Neuroblastoma, Ganglioneuroblastoma","enrollment":15},{"nctId":"NCT04750239","phase":"PHASE1, PHASE2","title":"Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer","status":"TERMINATED","sponsor":"Y-mAbs Therapeutics","startDate":"2021-08-17","conditions":"SCLC","enrollment":3},{"nctId":"NCT01419834","phase":"PHASE1","title":"Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-08-15","conditions":"Neuroblastoma","enrollment":68},{"nctId":"NCT05782959","phase":"PHASE1","title":"Phase 1 Study of BCD-245 in Subjects With Neuroblastoma","status":"UNKNOWN","sponsor":"Biocad","startDate":"2021-11-29","conditions":"Neuroblastoma","enrollment":24},{"nctId":"NCT03209869","phase":"PHASE1","title":"Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2018-03-12","conditions":"Neuroblastoma, Relapsed Neuroblastoma, Recurrent Neuroblastoma","enrollment":""},{"nctId":"NCT00072358","phase":"PHASE2","title":"Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-07","conditions":"Neuroblastoma","enrollment":291},{"nctId":"NCT00492167","phase":"PHASE1","title":"Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-09-09","conditions":"Neuroblastoma","enrollment":45},{"nctId":"NCT01662804","phase":"PHASE1","title":"Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-08-06","conditions":"Neuroblastoma","enrollment":14},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300},{"nctId":"NCT01704872","phase":"PHASE1","title":"ch14.18/CHO Bridging Study","status":"COMPLETED","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2005-07","conditions":"Neuroblastoma","enrollment":16},{"nctId":"NCT01701479","phase":"PHASE1, PHASE2","title":"Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2012-01","conditions":"Neuroblastoma","enrollment":288},{"nctId":"NCT02100930","phase":"NA","title":"Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-03","conditions":"Neuroblastoma","enrollment":69},{"nctId":"NCT01183897","phase":"PHASE2","title":"3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08-12","conditions":"Neuroblastoma","enrollment":31},{"nctId":"NCT01576692","phase":"PHASE1","title":"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-04","conditions":"Neuroblastoma","enrollment":34},{"nctId":"NCT02130869","phase":"PHASE1","title":"A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-10-10","conditions":"Neuroblastoma, Lymphoma, High-risk Tumor","enrollment":8},{"nctId":"NCT00743496","phase":"PHASE1","title":"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-10-08","conditions":"Neuroblastoma, Melanoma, Osteosarcoma","enrollment":50},{"nctId":"NCT01123304","phase":"PHASE1","title":"Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma","status":"TERMINATED","sponsor":"Morphotek","startDate":"2010-05","conditions":"Melanoma","enrollment":18},{"nctId":"NCT00004110","phase":"PHASE2","title":"Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1999-08","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00450307","phase":"PHASE1","title":"Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-06","conditions":"Neuroblastoma","enrollment":32},{"nctId":"NCT00003022","phase":"PHASE1","title":"Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-04","conditions":"Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer","enrollment":""},{"nctId":"NCT00002634","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1995-02","conditions":"Neuroblastoma","enrollment":45},{"nctId":"NCT00002560","phase":"PHASE2","title":"Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1994-02","conditions":"Neuroblastoma","enrollment":40},{"nctId":"NCT00002458","phase":"PHASE2","title":"Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1987-11","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00004184","phase":"PHASE1, PHASE2","title":"Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"1998-08","conditions":"Melanoma (Skin)","enrollment":50},{"nctId":"NCT00040872","phase":"PHASE2","title":"Multiple Therapies in Treating Patients With Advanced Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-06","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00037011","phase":"PHASE1","title":"Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-11","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00003023","phase":"PHASE1","title":"Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-03","conditions":"Neuroblastoma, Sarcoma","enrollment":24},{"nctId":"NCT00089258","phase":"PHASE2","title":"Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-07","conditions":"Neuroblastoma","enrollment":74},{"nctId":"NCT00005576","phase":"PHASE1","title":"Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-01","conditions":"Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma","enrollment":6},{"nctId":"NCT00045617","phase":"PHASE2","title":"S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2003-01","conditions":"Lung Cancer","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"monoclonal antibodies GD2","genericName":"monoclonal antibodies GD2","companyName":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","companyId":"federal-research-institute-of-pediatric-hematology-oncology-and-immunology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth. Used for Neuroblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}